Zoetis Posts Better Than Expected Q4 Earnings On Higher Companion Animal Products, Issues Upbeat Annual Guidance

  • Zoetis Inc ZTS has reported Q4 FY22 revenue of $2.04 billion, an increase of 4% Y/Y, beating the consensus of $2.01 billion.
  • Adjusted EPS was $1.15, up 15% Y/Y, beating the consensus of $1.05.
  • "We grew revenue 8% operationally, driven by our innovative companion animal franchises across parasiticides, dermatology and pain. We also grew our adjusted net income faster than sales for the year, at 11% operationally, while continuing to support investments in R&D, manufacturing capacity, and sales and marketing efforts that will drive future growth," said Kristin Peck, CEO.
  • Revenue in the U.S. segment was $1.112 billion, an increase of 7%. Sales of companion animal products increased by 12%, driven by growth in the parasiticide portfolio, primarily Simparica Trio for dogs.
  • Guidance: Zoetis expects FY23 revenues of $8.575- $8.725 billion compared to the consensus of $8.57 billion, with operational growth of 6%-8%.
  • The company forecasts adjusted EPS of $5.34-$5.44 versus the consensus of $5.33.
  • Price Action: ZTS shares are up 3.60% at $169.00 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareMoversGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!